Flag of the European Union EU Clinical Trials Register Help

Clinical trials for HPV

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    289 result(s) found for: HPV. Displaying page 1 of 15.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-001314-15 Sponsor Protocol Number: V503‐010 Start Date*: 2014-01-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, administered in P...
    Medical condition: This study is to study the tolerability and immunogenicity of V503, specific conditions (effiecacy endpoints) are not being investigated in this study.
    Disease:
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Completed) NO (Completed) DK (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-002945-10 Sponsor Protocol Number: V501-020 Start Date*: 2005-02-18
    Sponsor Name:Suomen MSD OY
    Full Title: A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the I...
    Medical condition: Prevention of Human Papillomavirus Infections
    Disease: Version SOC Term Classification Code Term Level
    7.0 10063001 LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FI (Completed) SE (Completed) DE (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003358-25 Sponsor Protocol Number: PC10VAC02 Start Date*: 2013-11-25
    Sponsor Name:Genticel
    Full Title: A double-blind, randomised, placebo-controlled, Phase II study to evaluate ProCervix efficacy to clear HPV 16 and HPV 18 infection in women with normal cytology or ASCUS/LSIL
    Medical condition: Women infected by HPV 16 and/or HPV 18 with normal cytology or ASCUS/LSIL
    Disease: Version SOC Term Classification Code Term Level
    17.1 10022891 - Investigations 10064328 Human papilloma virus test positive PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) GB (Completed) FI (Completed) DE (Completed) NL (Ongoing) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023393-39 Sponsor Protocol Number: GDS01C Start Date*: 2011-01-13
    Sponsor Name:Sanofi Pasteur MSD S.N.C
    Full Title: A Randomized, Double-Blinded, Controlled with GARDASIL® (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Toler...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) Types 6, ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066416 Vulvovaginal human papilloma virus infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: FI (Completed) BE (Completed) SE (Completed) ES (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002758-22 Sponsor Protocol Number: V503-003 Start Date*: 2012-12-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to ...
    Medical condition: Prevention of external genital lesions, anal cancers and related precancers, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52 and 58.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FI (Not Authorised) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003135-36 Sponsor Protocol Number: CYD67 Start Date*: 2019-10-31
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia
    Medical condition: Dengue Fever Dengue Hemorrhagic Fever Human Papillomavirus Disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-004933-14 Sponsor Protocol Number: V502-003-01 Start Date*: 2006-11-13
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus (HPV) L...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 45, 52, and 58.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011617-25 Sponsor Protocol Number: V503-002 Start Date*: 2009-10-16
    Sponsor Name:MSD Finland Oy
    Full Title: A Study to Demonstrate Immunogenicity, Tolerability, and Manufacturing Consistency of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered in Preadolescents an...
    Medical condition: Cervical Cancer
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed) AT (Completed) SE (Completed) ES (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002932-42 Sponsor Protocol Number: V501-110-01 Start Date*: 2016-12-14
    Sponsor Name:MSD K.K., a subsidiary of Merck & Co., Inc
    Full Title: A Phase IV Open-label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 ...
    Medical condition: Human Papillomavirus infection
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003852-13 Sponsor Protocol Number: V504-001-00 Start Date*: 2007-11-09
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus- Like Particle (VLP) Vaccine (V504) Administered Concomitantly with GARDASIL...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52, an...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063001 Human papilloma virus infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001890-98 Sponsor Protocol Number: HPV001 Start Date*: 2020-05-29
    Sponsor Name:Vaccitech Ltd.
    Full Title: A Phase 1b/2 Randomised, Placebo-controlled, Dose-ranging Study to Evaluate Safety, Tolerability and Immunogenicity of a Chimpanzee Adenovirus (ChAdOx1)-vectored Multigenotype High Risk Human Papil...
    Medical condition: Persistent hrHPV infection in participants with low grade cervical lesions
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005717-23 Sponsor Protocol Number: V501-018-00 Start Date*: 2015-12-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL™ (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL™ at 9-18 Years of Age
    Medical condition: HPV
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-002546-20 Sponsor Protocol Number: 104820 Start Date*: 2006-11-02
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ HPV 16/18 L1/AS04 vaccine administered intramuscularly ac...
    Medical condition: For active immunization of girls and women from 10 years of age onwards for the prevention of persistent human papillomavirus (HPV) infections and related clinical outcomes (cytological abnormaliti...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004581-16 Sponsor Protocol Number: V501-030 Start Date*: 2015-04-02
    Sponsor Name:Merck Sharp & Dohme (China) Ltd.
    Full Title: An Immunogenicity and Safety Study of GARDASIL™ in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years
    Medical condition: Prevention of HPV types 6, 11, 16 and 18 related cervical cancer, vulvar, vaginal pre-cancers, low-grade, pre-cancerous lesions, and genital warts in Chinese female subjects aged 9 to 45 years and ...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002083-13 Sponsor Protocol Number: HPVfollowup Start Date*: 2016-07-21
    Sponsor Name:Public Health England
    Full Title: An observational follow up study of a randomised parallel group phase IV study to evaluate the duration of the immune response to vaccine and non-vaccine HPV types in UK adolescent females who rece...
    Medical condition: No specific medical condition - immune reponses to HPV vaccination.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10071146 Human papilloma virus immunisation PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000111-16 Sponsor Protocol Number: V501-029 Start Date*: 2017-01-11
    Sponsor Name:Merck & Co., Inc.
    Full Title: Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in healthy females 9 to 15 years of age in India.
    Medical condition: vaccination against HPV infection/related disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-001843-37 Sponsor Protocol Number: 52649 Start Date*: 2019-08-06
    Sponsor Name:Radboud University Medical Center
    Full Title: Imaging of tumour microenvironment in patients with oropharyngeal head and neck squamous cell carcinoma using RGD PET/CT imaging.
    Medical condition: The aim of this study is to assess differences in tumour microenvironment between HPV positive and HPV negative oropharyngeal head and neck squamous cell carcinoma using [68Ga]Ga-RGD2 PET/CT and p...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031117 Oropharyngeal squamous cell carcinoma stage III LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031112 Oropharyngeal squamous cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031116 Oropharyngeal squamous cell carcinoma stage II LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031115 Oropharyngeal squamous cell carcinoma stage I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-003528-39 Sponsor Protocol Number: V503-001 Start Date*: 2007-11-15
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavi...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, ...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Completed) SE (Completed) DE (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001963-35 Sponsor Protocol Number: MET50 Start Date*: 2016-05-06
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
    Medical condition: Healthy volunteers (active immunization against invasive meningococcal disease (IMD) caused by Meningococcal serogroups A, C, Y or W
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-006002-27 Sponsor Protocol Number: CHUBX2011/18 Start Date*: 2012-07-31
    Sponsor Name:CHU de Bordeaux
    Full Title: Multicentre trial evaluating the immunogenicity of HPV vaccination in girls on immunosuppressive therapy.
    Medical condition: Infection by HPV 6, 11, 16, 18
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 11:41:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA